Targeting PPARalpha in Alzheimer's Disease.

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Alzheimer's disease (AD) pathogenesis involves complex molecular mechanisms beyond the amyloid cascade.
• Peroxisome proliferator-activated receptors (PPARs) are key regulators of CNS processes including metabolism and redox homeostasis.
• PPARα is emerging as a significant therapeutic target for AD, with limited prior research.

Purpose of the Study:

• To review the role of PPARα agonists in modulating Alzheimer's disease (AD) pathogenetic mechanisms.
• To highlight the therapeutic potential of PPARα in AD treatment strategies.
• To provide an update on current research regarding PPARα in AD.

Main Methods:

• Review of in vitro and in vivo studies on PPARα agonists in Alzheimer's disease models.
• Analysis of literature on the effects of PPARα activation on key AD pathways.
• Synthesis of evidence on PPARα's impact on amyloidogenesis, tau phosphorylation, and neuroinflammation.

Main Results:

• PPARα activation inhibits the amyloidogenic pathway and tau hyperphosphorylation.
• PPARα agonists reduce neuroinflammation and oxidative stress.
• PPARα modulates glucose and lipid metabolism and enhances autophagy in AD contexts.

Conclusions:

• PPARα agonists demonstrate multifaceted therapeutic potential for Alzheimer's disease.
• Targeting PPARα offers a promising strategy to address multiple AD pathologies.
• Further research into PPARα modulators could lead to novel AD treatments.